The stock price of Zenas Biopharma Inc (NASDAQ: ZBIO) has surged by 11.82% when compared to previous closing price of $9.14, but the company has seen a 0.29% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-20 that WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on June 16, 2025 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 112,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
Is It Worth Investing in Zenas Biopharma Inc (NASDAQ: ZBIO) Right Now?
Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ZBIO is 10.20M, and currently, short sellers hold a 48.14% ratio of that floaft. The average trading volume of ZBIO on July 03, 2025 was 192.30K shares.
ZBIO’s Market Performance
ZBIO’s stock has seen a 0.29% increase for the week, with a 1.59% rise in the past month and a 34.47% gain in the past quarter. The volatility ratio for the week is 8.84%, and the volatility levels for the past 30 days are at 8.92% for Zenas Biopharma Inc The simple moving average for the last 20 days is -0.05% for ZBIO stock, with a simple moving average of -11.39% for the last 200 days.
Analysts’ Opinion of ZBIO
Many brokerage firms have already submitted their reports for ZBIO stocks, with Wedbush repeating the rating for ZBIO by listing it as a “Outperform.” The predicted price for ZBIO in the upcoming period, according to Wedbush is $35 based on the research report published on March 20, 2025 of the current year 2025.
Wolfe Research, on the other hand, stated in their research note that they expect to see ZBIO reach a price target of $19. The rating they have provided for ZBIO stocks is “Outperform” according to the report published on February 04th, 2025.
H.C. Wainwright gave a rating of “Buy” to ZBIO, setting the target price at $30 in the report published on December 16th of the previous year.
ZBIO Trading at 0.06% from the 50-Day Moving Average
After a stumble in the market that brought ZBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.07% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZBIO starting from MOULDER LEON O JR, who purchase 25,000 shares at the price of $6.67 back on Feb 18 ’25. After this action, MOULDER LEON O JR now owns 266,155 shares of Zenas Biopharma Inc, valued at $166,750 using the latest closing price.
Xiao Ting, the Director of Zenas Biopharma Inc, purchase 10,000 shares at $7.76 during a trade that took place back on Feb 07 ’25, which means that Xiao Ting is holding 47,000 shares at $77,600 based on the most recent closing price.
Stock Fundamentals for ZBIO
Current profitability levels for the company are sitting at:
- -11.58 for the present operating margin
- 0.33 for the gross margin
The net margin for Zenas Biopharma Inc stands at -10.86. The total capital return value is set at -0.61. Equity return is now at value -115.47, with -85.03 for asset returns.
Based on Zenas Biopharma Inc (ZBIO), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -112.35.
Currently, EBITDA for the company is -163.75 million with net debt to EBITDA at 1.13. When we switch over and look at the enterprise to sales, we see a ratio of 15.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.47.
Conclusion
In a nutshell, Zenas Biopharma Inc (ZBIO) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
